SEC Form 4 · accession 0001209191-15-061705
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew M Loar
Officer — Chief Financial Officer
Period of report
Jul 20, 2015
Accepted (ET)
Jul 20, 2015 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $1.37 | Jul 20, 2015 | A | 150,000 | A | — | Jul 20, 2025 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1Mr. Loar was awarded options to purchase shares of OXiGENE, Inc. common stock, $0.01 par value per share (the "Stock Options"), pursuant to the OXiGENE, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer.
- F2The first 25% of the Stock Options vest on the first anniversary of the grant date, and the remainder will vest monthly in 36 substantially equal installments starting one month after the first anniversary of the grant date, such that the Stock Options will be 100% vested as of the fourth anniversary of the grant date.